Chlamydia trachomatis is a bacterial pathogen that is a major cause of blindness and infertility in diverse populations across the world. In an effort to model genetic complexities that are observed in human populations and to identify novel genes involved in susceptibility to C. trachomatis, we have adapted a murine model of systemic infection for use in genetic analysis. In this model, chlamydial colonization and replication is measured in the spleens of mice shortly after intravenous delivery of C. trachomatis L2. Here, we show that C57BL/6J and C3H/HeJ inbred mice are differentially susceptible to this systemic infection. Additionally, fibroblasts cultured from C57BL/6J and C3H/HeJ embryos are differentially permissive for chlamydial replication. We have taken advantage of this natural variation to map quantitative trait loci on Chromosomes 2, 3, and 11 that segregate with the bacterial load in F2 cross progeny during the acute phase of C. trachomatis infection in vivo. To validate our mapping results, we also generated mice that are congenic for a portion of Chromosome 11 from the susceptible parent. This congenic interval confers increased susceptibility to C. trachomatis, both in vivo and in vitro, suggesting that our screen identified at least one gene that is involved in cellular resistance to C. trachomatis replication.
Introduction
Chlamydia trachomatis is an obligate intracellular bacterial pathogen that causes a wide range of diseases in humans. Depending upon the serovar that infects the host, C. trachomatis can cause infection of either the ocular or genital mucosa. Serovars A-C are responsible for the ocular infection, trachoma, which is the leading cause of preventable blindness in the world. In contrast, serovars D-K are associated with inflammation and pathology in the genital tract that leads to urethritis, cervicitis, pelvic inflammatory disease, and infertility. In developing countries, genital infection can also be caused by the lymphogranuloma venereum serovars L1-L3. These highly-invasive serovars quickly reach the draining lymph nodes of the genital tract and spread systemically throughout the host. 1 A defining characteristic of chlamydiae is their unique biphasic developmental cycle. Outside of the host cell, C. trachomatis exists as infectious, but metabolically quiescent elementary bodies (EBs). Once EBs enter the host cell, they convert within hours to noninfectious reticulate bodies that are metabolically active and replicate within a specialized vacuole known as an inclusion. Approximately 16-20 h following infection, the reticulate bodies begin to convert back to EBs. By 36-48 h postinfection, the host cell lyses and EBs are released into the extracellular space to begin further rounds of infection and replication. 2 Exposure to chlamydiae can be common, especially in endemic regions, although it is clear that exposure does not necessarily lead to disease in every individual. Similarly, even among those that develop disease, the duration and severity of pathology may vary substantially from one individual to the next. 3, 4 Host genetic factors likely play an important role in this variability, and indeed, human genetic studies have shown associations between increased prevalence or severity of Chlamydia infection and certain human leukocyte antigen haplotypes [5] [6] [7] [8] or polymorphisms in CD-14, tumor necrosis factor-a, or interleukin-10. [8] [9] [10] Although these reports show associations that are likely to be relevant, it is difficult to confirm their biological significance using human studies.
Genetic manipulation of Chlamydia is not currently possible; therefore, genetic studies of chlamydial pathogenesis must focus instead on host models of infection. Indeed, murine infection models provide an important set of tools to identify host factors that function in response to Chlamydia spp. and have revealed interesting differences in susceptibility among inbred mouse strains across a range of infection models. For example, there is variability among several inbred strains in susceptibility to genital tract infection with serovars of C. trachomatis.
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Recent experiments with the mouse pneumonitis (MoPn) biovar of C. trachomatis have demonstrated that this variability is partly related to the cytokine profile in the genital tract during infection. C57BL/6 mice, which exhibit relatively mild pathological outcomes when compared to BALB/c or C3H/HeN mice, seem to have a more vigorous Th1 response with higher levels of tumor necrosis factor-a, interferon-g, and macrophage inflammatory protein-1a. [15] [16] [17] Analysis of genetically modified mice has also demonstrated the importance of certain immune factors in the host response to Chlamydia infection. For example, mice that are deficient for cytokines like interferon-g or interleukin-12, or key immune molecules like major histocompatibility complex class II or CD-8, show increased susceptibility to various types of Chlamydia infections (reviewed in Rottenberg et al.
18
). Studies using congenic mice have also demonstrated the effect of major histocompatibility complex haplotype on susceptibility to Chlamydia spp. (our unpublished observations). 19 Although the mouse studies described above provide important clues about the roles played by specific cytokines and immune molecules under certain infection conditions, they supply only limited information about the wide range of factors that might be involved in the host response to Chlamydia. In contrast, genetic analysis represents an unbiased approach to identifying genes important for resistance to infection, from conventional immune sensors and effectors to non-immune proteins that may nonetheless influence the ability of Chlamydia to cause disease. Indeed, for many pathogens, classical mouse genetics has served as a valuable tool for the dissection of host factors involved in the response to infection. 20, 21 In an effort to apply the host genetics approach to Chlamydia pathogenesis, and to identify novel genes involved in resistance or susceptibility to Chlamydia, we have adapted a systemic model of C. trachomatis infection for use in genetic analysis. 22 In this model, mice are injected intravenously with C. trachomatis L2, and the ensuing infection is monitored in the spleen during the acute phase of the infection. This model system is particularly well suited for genetic analysis of the host response to infection because C. trachomatis reliably and predictably colonizes the spleen within hours of intravenous delivery. C3H mice support more chlamydial replication than C57BL/6 mice, and this difference emerges very early in the course of infection. We have exploited this early strain difference to map three quantitative trait loci (QTL) that appear to affect the ability of the host to restrict chlamydial replication during the acute phase of the infection. Therefore, this difference is unlikely to involve differences in the function of acquired immunity. Furthermore, we validated the use of this genetic approach by showing that one of our loci seems to impact resistance to C. trachomatis in fibroblasts isolated from embryos congenic for one of our QTL. Together, our data provide an important first step towards identifying novel genes involved in susceptibility to C. trachomatis and demonstrate the utility of host genetics in identifying loci that function in resistance to pathogens.
Results
The course of systemic C. trachomatis infection differs in the spleens of C57BL/6J and C3H/HeJ mice We were interested in developing a genetically tractable model of susceptibility to C. trachomatis that would allow us to identify genes involved in resistance to this pathogen. To that end, we infected C57BL/6J and C3H/HeJ inbred mice via the tail vein with C. trachomatis L2, and monitored the infection in the spleens of these mice. To assay chlamydial colonization and replication during the acute phase of the infection, we devised a multiplex, real-time quantitative PCR assay that allowed us to simultaneously determine the amount of Chlamydia and host DNA as a measure of bacterial load in the spleens of infected animals. In preliminary experiments involving known amounts of C. trachomatis and host tissue, we found this assay to be a sensitive and reliable measure of chlamydial load (not shown). When we applied the PCR assay to infected mice within hours postinfection, we found that the amount of C. trachomatis present in the spleens of C57BL/6J and C3H/HeJ mice is similar at 6, 10 and 12 h postinfection ( Figure 1) . By 14 h postinfection, however, there is roughly fourfold more C. trachomatis in the spleens of C3H/HeJ mice relative to C57BL/6J mice; this difference increases to more than 10-fold by 20 h postinfection.
In separate experiments, we carried the infection out to 17 days postinfection and assessed chlamydial load in the spleens of infected mice using standard titering methods. We found that more C. trachomatis can be titered from the spleens of C3H/HeJ mice relative to C57BL/6J mice at 3, 7 and 10 days postinfection ( Figure 2 ). Furthermore, while C57BL/6J mice clear the splenic infection by 12 days postinfection, infectious particles can be titered from C3H/HeJ spleens beyond 17 days postinfection. Preliminary genetic mapping experiments involving day 17 splenic titers taken from a small number of backcross progeny revealed a complex trait that was only partly explained by suggestive linkages to the major histocompatibility complex on Chromosome 17 and to another locus on Chromosome 6 (data not shown).
The strain difference in susceptibility to C. trachomatis can be recapitulated in vitro using primary cells We reasoned that certain elements of the in vivo susceptibility difference might be modeled in vitro using primary cells derived from the parental strains. To test this hypothesis, we prepared mouse embryonic fibro- Genetic analysis of susceptibility to C. trachomatis in mouse I Bernstein-Hanley et al blasts (MEFs) from C57BL/6J and C3H/HeJ, infected them in culture with C. trachomatis L2, and assessed chlamydial replication by measuring the amount of Chlamydia DNA present in the cells using our quantitative PCR assay. Under standard culture conditions, we found that MEFs from both strains were equally permissive for chlamydial replication (not shown). Therefore, we elected to pretreat the cells with interferon-g, a cytokine that is critical to the host response to Chlamydia infection, 18 and that might not otherwise be present in sufficient quantities in our fibroblast cultures. Exogenous interferon-g markedly reduced the amount of chlamydial growth that took place in both MEF strains; however, the presence of interferon-g rendered C57BL/6J MEFs comparatively more resistant to chlamydial replication than C3H/HeJ MEFs ( Figure 3 ). Furthermore, when we looked at the cells by immunofluorescent microscopy at 29 h postinfection, we observed that this difference is related to a greater number of mature inclusions in C3H/HeJ MEFs relative to C57BL/6J MEFs and not to any discernable differences in inclusion size or morphology (not shown). Given that this in vitro effect is dependent upon the presence of interferon-g, and that interferon-g is not likely to be involved in uptake of Chlamydia into the cells, we hypothesize that the block in inclusion development in C57BL/6J MEFs is at the level of replication and not entry.
Susceptibility to C. trachomatis segregates as a complex trait in the F2 generation To dissect the genetic origins of the in vivo susceptibility difference between C57BL/6J and C3H/HeJ, we infected 169 F2 progeny with C. trachomatis L2 and assessed chlamydial load in the spleens of these mice at 29 h postinfection, a time point that would allow us to capture host genetic differences operative during the acute phase of the infection. When assayed at 29 h postinfection, the amount of C. trachomatis in the spleens of these F2 mice exhibited a continuous distribution with a mean of 10.4475.69 pg Chlamydia DNA/mg host DNA. As the F2 animals were injected in groups of 30-40 animals, and because there was subtle variability in the average phenotype from batch to batch, we elected to normalize the data by subtracting the group-specific mean from each animal. The mean of this new distribution is zero, with a standard deviation of 5.30.
Each animal was initially genotyped at 93 simple sequence length polymorphism (SSLP) markers spaced an average of 16 centimorgans (cM) across the 19 autosomes; additional markers were subsequently added to the map to improve the resolution around linkage peaks. We then performed QTL analysis using MapManager QTX 23 to determine regions of the genome that segregated with the normalized phenotypes described above. A permutation test based on our data established a genome-wide significance level of P ¼ 0. 25 for the reporting of significant QTL results. Accordingly, we have named the Chromosome 2, 3 and 11 loci, respectively: Ctrq-1, Ctrq-2, and Ctrq-3 for C. trachomatis resistance QTL. All other regions of the genome were LRS o14.0, ns.
Examination of the phenotype:genotype correlation at a marker near each linkage peak illustrates the phenotypic effect and the dominance relationships of the alleles at each QTL (Table 1) . Thus, Ctrq-1 and Ctrq-3 are, respectively, recessive and dominant susceptibility alleles from the susceptible parent (C3H/HeJ). Ctrq-2, meanwhile, is a dominant allele from C3H/HeJ that seems to confer relative resistance to C. trachomatis.
To determine the feasibility of fine mapping studies aimed at identifying the relevant polymorphic gene(s) under each linkage peak, we constructed a B6.C3H congenic mouse line that carries a portion of Chromosome 11 from C3H/HeJ between D11Mit20 and D11Mit245 within a C57BL/6J background. This congenic interval contains the entire 71.5 LOD support interval for Ctrq-3 ( Figure 4 ). We injected heterozygous carriers of this congenic interval with C. trachomatis and found that at 29 h postinfection, there was significantly more Chlamydia in the spleens of these mice than in the spleens of noncarrier littermates ( Figure 5 ). Furthermore, MEFs that are heterozygous for this congenic interval support more chlamydial replication in our in vitro assay than do noncarrier controls ( Figure 5 ).
Discussion
C. trachomatis is a significant cause of disease in a variety of human populations. In an effort to identify novel host genes involved in resistance to acute C. trachomatis infection, we have adapted a systemic model of C. trachomatis infection in mouse for use in genetic analysis.
In this study, we demonstrated that although C. trachomatis L2 colonizes the spleens of C57BL/6J and C3H/HeJ mice to a similar extent, more C. trachomatis is present in the spleens of C3H/HeJ mice relative to C57BL/6J mice starting at 14 h postinfection and persisting beyond 17 days postinfection (Figures 1 and 2 ). This difference correlates with an in vitro, interferon-gdependent difference in susceptibility between fibroblasts isolated from the two strains ( Figure 3 ). We applied standard genetic mapping to the in vivo strain difference, and identified three significant QTL that segregate with the bacterial load in the spleens of F2 mice at 29 h postinfection (Figure 4 ). These QTL represent the first host loci involved in the in vivo response to C. trachomatis to be identified using an unbiased genomewide approach. As in other genetic screens, the QTL that emerged from our screen are almost certainly a function of the Figure 5 Effect of Chromosome 11 congenic interval on susceptibility to C. trachomatis, both in vitro (left) and in vivo (right). Data for control noncarrier samples are shown as hatched bars, whereas data for congenic samples are shown as solid black bars. In vitro data are the amount of Chlamydia DNA amplified from embryonic fibroblasts infected for 28 h with C. trachomatis L2 after interferon-g treatment, as described in Materials and methods. In vivo data are the amount of Chlamydia DNA per unit weight of host DNA amplified from the spleens of infected mice 29 h after intravenous delivery of C. trachomatis L2. Each bar is mean of at least three data points; error bars represent one standard deviation. Samples with identical symbol above error bars are significantly different at Po0.01.
Genetic analysis of susceptibility to C. trachomatis in mouse I Bernstein-Hanley et al particular features of the infection model that we employed. Thus, a defining characteristic of our mapping project is that we chose to focus on early events in the infection, thereby offering unique insight into factors that regulate initial and presumably critical steps in the infection process. These steps might include colonization of C. trachomatis in the spleen, attachment and entry into the relevant cell type(s), proper intracellular targeting, and various other intracellular events that lead to productive chlamydial replication. The nature of our screen did not allow the identification of genes that are specifically involved in acquired immunity against Chlamydia infection. However, genes that act early may nonetheless shape or participate directly in later stages of the immune response; thus, despite our focus on early events in the infection, we may have in fact identified loci that function in more chronic infections as well. Indeed, we observed a strain difference in a chronic model of infection, a difference that may be related to the acute differences that we mapped. Eventual identification and analysis of our QTL will be critical in determining their relevance in chronic C. trachomatis infection.
Infections caused by C. trachomatis are diverse and cannot be encapsulated in a single model system. Still, the model used in our genetic analysis captures elements of the lymphatic colonization and replication that typifies infection with a lymphogranuloma venereum biovar of C. trachomatis. Furthermore, it is worth emphasizing that the effects we mapped may generalize to other types of infections, such as those of the ocular and genital tract epithelia by the trachoma biovars of C. trachomatis. For example, the particular inbred mouse strains that we analyzed have similar documented differences in susceptibility to other Chlamydia infections, including respiratory tract infection with C. trachomatis MoPn and genital tract infection with C. trachomatis MoPn and serovar E. 11, 15, 16 These findings suggest that the mechanisms regulating the difference in susceptibility between C57BL/6J and C3H/HeJ may be relatively general and that the effects of the loci we identified will not be specific to splenic infection with C. trachomatis L2.
One reason why C57BL/6J and C3H/HeJ exhibit differences in susceptibility across a range of infection models may be related to the susceptibility difference that we observed between fibroblasts prepared from these two strains (Figure 3) . Indeed, given that the Chlamydia developmental cycle is remarkably wellconserved across different Chlamydia serovars and species, 2 it seems likely that the host-pathogen interactions that occur in fibroblasts infected with C. trachomatis L2 would be preserved across a variety of cell types infected with different serovars of C. trachomatis. This allows for the possibility that polymorphisms in host genes that interact with the chlamydial developmental cycle might positively or negatively affect growth and replication across a variety of different cell types.
That the in vitro difference in susceptibility to C. trachomatis is interferon-g-dependent suggests a strain difference in interferon responsiveness between fibroblasts isolated from C57BL/6J and C3H/HeJ. Interferong is a major inflammatory cytokine involved in the host response to Chlamydia infection and regulates aspects of both innate and acquired immunity against Chlamydia.
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Marked interstrain differences in interferon responsiveness under similar conditions have been described once previously, when Qiu et al. 11 found that growth of C. trachomatis MoPn was less inhibited by interferon-g in peritoneal macrophages isolated from C3H than in macrophages isolated from C57BL/6. This difference was associated with greater nitric oxide production in C57BL/6 macrophages relative to C3H macrophages, though nitric oxide production was not sufficient to fully explain the susceptibility difference between the two strains. Nelson et al. 26 recently showed that the small interferon-g-inducible GTPase Iigp1 was a critical component of the inhibitory effect of interferon-g on growth of C. trachomatis L2 in primary mouse epithelial cells. The role of Iigp1 in the susceptibility difference we observed between C57BL/6J and C3H/HeJ MEFs remains unclear; however, none of our QTL map in the vicinity of Iigp1, suggesting that we have identified novel host loci involved in cellular resistance to C. trachomatis replication (see below).
Identification of the causative polymorphism(s) underlying our three QTL will require construction of congenic mice that harbor an interval of donor DNA within the genomic background of a recipient strain. After confirming a phenotypic effect of this larger interval, recombination analysis can then be carried out to identify the smallest interval still capable of conferring the donor phenotype. This method has been used in the mouse to localize and identify QTL involved in type 1 diabetes, tumor susceptibility, and a variety of other multigenic or continuously varying traits (reviewed in Flint et al.
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). To commence a similar analysis in this study, and to validate our mapping results, we introgressed more than 30 megabases of C3H/HeJ DNA around the Ctrq-3 locus into a C57BL/6J background and found that this interval confers increased susceptibility to C. trachomatis, both in vivo and in vitro ( Figure 5 ). This result reinforces our genetic mapping data and affirms our ability to perform fine mapping studies to identify the causative polymorphisms that affect susceptibility C. trachomatis in our model.
It is also significant that the Ctrq-3 congenic interval confers susceptibility both in mice infected systemically and in MEFs infected in culture. This implies that the resistance mechanism governed by Ctrq-3 is cell autonomous in nature and can function in intracellular pathways affecting resistance to C. trachomatis. Additionally, this finding validates our model system as a useful representation of Chlamydia infection as it shows that our in vivo genetic screen was successful in identifying at least one QTL that seems important for intracellular replication of C. trachomatis. The fact that this locus can function in vitro should also accelerate identification and characterization of this QTL.
Finally, it is important to note that despite our identification of three significant QTL, the size of our cross precluded the identification of polymorphic genes that might have more subtle effects on susceptibility to C. trachomatis. Whereas an approximation of the experimental noise in our cross is complicated by an apparent effect of genotype on trait variance, we estimate that our three QTL explain about 50% of the total phenotypic variation that is attributable to genetic differences among our F2 progeny (see Materials and methods). This suggests the existence of other polymorphic genes of small effect that went undetected in our cross. It may be possible to utilize mice congenic for the Ctrq loci in additional screens for genes that may have been masked by these QTL of larger effect.
In sum, we utilized an unbiased genetic approach to identify three loci that influence susceptibility to C. trachomatis in mouse during the acute phase of infection. At least one of these loci seems to also influence susceptibility of embryonic fibroblasts to C. trachomatis, as mice and MEFs that are congenic for the susceptible allele of one of the QTL are rendered more susceptible to C. trachomatis. We anticipate that the identification of these loci will provide novel insight into the hostpathogen interactions that occur during the acute phase of C. trachomatis infection in mouse. A thorough understanding of these processes will be valuable in understanding the immunological and pathological mechanisms of chlamydial infection and disease in humans.
Materials and methods

Animals
Mice were obtained from The Jackson Laboratory (Bar Harbor, ME, USA) and maintained under specificpathogen-free conditions until infection. For some experiments, mice were housed and infected in a facility designed for holding pathogen-infected animals. Congenic mice described herein were commissioned from The Jackson Laboratory and were created through use of marker-assisted elimination of donor DNA; mice were phenotyped at generation N6.
Chlamydia trachomatis C. trachomatis serovar L2 434/Bu was propagated in the McCoy murine fibroblast cell line. McCoy cells were grown in Eagle's MEM supplemented with 10% fetal calf serum (FCS), 0.1 mM nonessential amino acids, 1 mM sodium pyruvate, and 1.5 g/l sodium bicarbonate. C. trachomatis elementary bodies were isolated from infected McCoy cells by density gradient centrifugation as previously described. 28 Infection Mice, 6-to 8-week-old, were injected into the tail vein with C. trachomatis L2 in 200 ml of sucrose-phosphateglutamic acid buffer (SPG, 220 mM sucrose, 12.5 mM phosphate, 4 mM l-glutamic acid, pH 7.5). Owing to technical difficulties associated with the calculation of titer values, the number of inclusion-forming units (IFUs) injected was variable though known: 10 7 IFUs were used in the time course experiments and for the congenics; 10 6 IFUs were used in the F2 cross. At various times postinfection, the mice were killed by CO 2 euthanasia, and their spleens were removed. For titering experiments, the spleens were promptly pressed through a mesh screen into sucrose-phosphate buffer (200 mM sucrose, 20.6 mM phosphate, pH 7.5) supplemented with 10% FCS, gentamicin, vancomycin, nystatin, and amphotericin B, and then flash-frozen. For quantitative PCR assessment of chlamydial load, intact spleens were flash-frozen. All samples were stored at À801C until processing.
Titering
The number of infectious C. trachomatis organisms present in the spleens of infected mice was determined as previously described. 29 Briefly, spleen homogenates were thawed, sonicated, and overlaid onto McCoy cell monolayers. Approximately 30 h later, the monolayers were fixed and stained with the Pathfinder Chlamydia Culture Confirmation System (Bio-Rad, Hercules, CA, USA) to visualize developing inclusions. The number of inclusions present on the monolayer was then used to calculate the number of IFUs per spleen.
Mouse embryonic fibroblasts Embryonic day 12.5-14.5 pups were removed from pregnant females that had been killed by CO 2 euthanasia. After removal of the head and fetal liver tissue, the pups were individually minced, trypsinized, and plated in DMEM supplemented with 10% FCS, 0.1 mm nonessential amino acids, and 0.1% b-mercaptoethanol. Cells were expanded and passaged in the same media in a humidified environment maintained at 371C, 5% CO 2 / 95% air. After two or more passages, cells were plated for infection; for some experiments, the media was supplemented with 10 U/ml of recombinant mouse interferon-g (Invitrogen, Frederick, MD, USA) for 15 h before infection. Cells were infected with C. trachomatis L2 at a multiplicity of infection of 2:1 in SPG by centrifugation at 1928 g for 1 h at 371C, and then returned to standard media. For analysis of Chlamydia growth, the monolayers were trypsinized, pelleted, and prepared for real-time PCR as described below. For immunofluorescent visualization of chlamydial inclusions, cells were plated and infected as above on coverglass, fixed with paraformaldehyde, permeabilized with Triton X-100, and stained using a mouse monoclonal antibody against C. trachomatis major outer membrane protein (Accurate Chemical & Scientific Corp., Westbury, NY, USA) and a rhodamineconjugated goat anti-mouse secondary antibody (Molecular Probes, Eugene, OR, USA). Cells were viewed at 500 Â magnification using a Zeiss Axioskop 2 microscope.
Quantitative PCR Total nucleic acid was prepared from homogenized spleens or trypsinized cell pellets using the QIAamp DNA Mini Kit from Qiagen (Valencia, CA USA). Samples were then subjected, in duplicate, to singleplex (cells) or multiplex (spleen) quantitative, real-time PCR on an ABI 7000 Sequence Detection System to assess the amount of Chlamydia and host DNA in the sample. 0 . Mouse GAPDH DNA was detected using the Rodent GAPDH Control Reagent Kit from Applied Biosystems (Foster City, CA, USA). Standard curves were generated in parallel from known amounts of C. trachomatis and murine DNA, and these curves were used to calculate the amount (pg) of Chlamydia DNA per unit weight (mg) of mouse DNA in the samples.
Genotyping and mapping SSLP markers for mapping were selected from the Broad Institute (http://www.broad.mit.edu) and Mouse Genome Informatics (MGI, http://www.informatics.jax.org). Genetic positions were obtained from the composite genetic map at MGI, and physical positions from the genomic assembly at The National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov). Many of the markers with polymorphism sizesX6 basepairs were amplified by standard PCR methods, and electrophoresed on 4% agarose gels; remaining markers were analyzed by fluorescent PCR on an ABI 3700 DNA Analyzer according to protocols furnished by the manufacturer. For genetic analysis, the genotype and corrected phenotype data (see Results) were entered into MapManager QTX. 23 Statistics and analysis Statistical regression was initially used to identify markers with linkage to the trait; where significant linkage was found, interval mapping was used to generate linkage data for regions between markers. The level of significance was based on a distribution of the linkage statistic generated from 10 5 random permutations of the data. Estimates of nongenetic variance (s 2 noise ) were used to infer the amount of the total variance attributable to genetic differences among our F2 animals (s À6 for the C57BL/6J animals and 1.48 Â 10 À5 for the C3H/HeJ animals. Thus, on average, 68% of the variance among our F2 animals could be attributed to genetic differences. Each of our QTL explained roughly 11% of the variance among our F2 animals; therefore, half of the genetic variance was accounted for by the three loci that we detected in our cross.
